title: Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand.
abstract: The objective of this study was to evaluate the immunogenicity and safety of a pentavalent vaccine (Pentaxim) containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Hib polysaccharide-conjugate (DTaP-IPV//PRP-T) antigens, in Thai children. One hundred eighty-six infants who had received a hepatitis B vaccine at birth were given a pentavalent vaccine at 2, 4 and 6 months of age and a hepatitis B vaccine concomitantly at 2 and 6 months of age. Immunogenicity was high for each vaccine antigen. The study vaccine was well tolerated and side effects were few. After the third dose, 100% of subjects had an anti-PRP > or = 0.15 microg/ml and 96.5% > or = 1.0 microg/ml; the anti-PRP GMT was 9.53 microg/ml. Seroprotective rates for diphtheria and tetanus (> or = 0.01 IU/ml) were 99.4% and 100%, respectively, and 100% for all three poliovirus types (> or = 8 1/dil U). The vaccine response rates to pertussis antigens (a 4-fold increase in antibody titer were 94.1% for PT and 93.0% for FHA. The DTaP-IPV//PRP-T vaccine given at 2, 4 and 6 months of age concomitantly with a monovalent hepatitis B vaccine, was well tolerated and highly immunogenic for primary immunization of infants in Thailand.
authors.affiliation: King Chulalongkorn Memorial Hospital, Bangkok, Tailand.
authors.forename: Usa
authors.initials: U
authors.lastname: Thisyakorn
authors.forename: Tawee
authors.initials: T
authors.lastname: Chotpitayasunondh
authors.forename: Chitsanu
authors.initials: C
authors.lastname: Pancharoen
authors.forename: Sunate
authors.initials: S
authors.lastname: Chuenkitmongkol
authors.forename: Esteban
authors.initials: E
authors.lastname: Ortiz
mesh_terms: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D023321:Poliovirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D013785:Thailand / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D017325:Hepatitis B Vaccines; D023321:Poliovirus Vaccines; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate